← Back to Search

Genotype-Guided Diet and Exercise for Cardiometabolic Health

N/A
Recruiting
Led By Pankaj Arora, MD, FAHA
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age more than or equal to 18
Consent to the collection of genetic material
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 days
Awards & highlights

Study Summary

This trial will study how well natriuretic peptides (hormones produced by the heart) work in people with a genetic variation that causes lower levels of these peptides.

Who is the study for?
This trial is for adults over 18 without a history of severe heart conditions like congestive heart failure, heart attack, or stroke. Participants should not be on insulin therapy but must be willing to follow the study protocol and consent to genetic material collection.Check my eligibility
What is being tested?
The GENESIS study is looking at how diet and exercise affect hormones produced by the heart called Natriuretic Peptides (NP), which are linked to cardiometabolic health. It will involve an exercise challenge, glucose challenge, and VO2 max determination.See study design
What are the potential side effects?
Since this trial involves dietary changes and physical challenges rather than medication, side effects may include muscle soreness from exercise or discomfort from dietary adjustments.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I agree to provide samples for genetic testing.
Select...
You agree to follow the rules of the study.
Select...
I have never had heart failure, a heart attack, or a stroke.
Select...
I do not take insulin.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Exercise Energy Expenditure between the high genotype and low genotype group.
Change in MRproANP levels following a standardized oral glucose challenge between the high genotype group and low genotype group.
Change in miR-425 levels following a standardized exercise challenge in those with low ANP genotype.
+1 more
Secondary outcome measures
Change in Resting Energy Expenditure (REE) between the two genotype groups.
Change in miR-425 levels with change in NP levels (ANP, MRproANP, BNP, and NTproBNP) following exercise challenge between the two genotype groups.
Change in miR-425 levels with change in NP levels (ANP, MRproANP, BNP, and NTproBNP) following exercise challenge.
+20 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Experimental: Low NP Genotype GroupExperimental Treatment4 Interventions
150 healthy adult participants with low NP genotype will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 5 days. On 5th day, the participants will come in for an exercise challenge test. On 6th day, participants will come in a fasting state and drink 75 gm of oral glucose, followed by blood collection every 8 hours.
Group II: Active Comparator: High NP Genotype GroupExperimental Treatment4 Interventions
50 healthy adult participants with high NP genotype will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 5 days. On 5th day, the participants will come in for an exercise challenge test. On 6th day, participants will come in a fasting state and drink 75 gm of oral glucose, followed by blood collection every 8 hours.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Study diet
2017
N/A
~90

Find a Location

Who is running the clinical trial?

National Heart, Lung, and Blood Institute (NHLBI)NIH
3,838 Previous Clinical Trials
47,851,454 Total Patients Enrolled
1 Trials studying Cardiometabolic Diseases
29 Patients Enrolled for Cardiometabolic Diseases
University of Alabama at BirminghamLead Sponsor
1,590 Previous Clinical Trials
2,281,282 Total Patients Enrolled
1 Trials studying Cardiometabolic Diseases
5 Patients Enrolled for Cardiometabolic Diseases
Pankaj Arora, MD, FAHAPrincipal InvestigatorUniversity of Alabama at Birmingham
5 Previous Clinical Trials
1,084 Total Patients Enrolled

Media Library

Glucose Challenge Clinical Trial Eligibility Overview. Trial Name: NCT05216042 — N/A
Cardiometabolic Diseases Research Study Groups: Experimental: Low NP Genotype Group, Active Comparator: High NP Genotype Group
Cardiometabolic Diseases Clinical Trial 2023: Glucose Challenge Highlights & Side Effects. Trial Name: NCT05216042 — N/A
Glucose Challenge 2023 Treatment Timeline for Medical Study. Trial Name: NCT05216042 — N/A
Cardiometabolic Diseases Patient Testimony for trial: Trial Name: NCT05216042 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are new participants able to join this research endeavor?

"Affirmative, the information found on clinicaltrials.gov reveals that this research is currently recruiting subjects. This study was initially posted on June 1st 2022 and has since been updated to its most recent version as of July 6th 2022. 200 participants are being recruited from just a single site for participation in this trial."

Answered by AI

What is the current intake capacity of this research endeavor?

"Confirmed. Clinicaltrials.gov provides evidence of the study's active recruitment status, which began on June 1st 2022 and was last edited 7 days later. The research team is looking for 200 individuals to participate at a single site."

Answered by AI

Who else is applying?

What state do they live in?
Alabama
How old are they?
18 - 65
What site did they apply to?
University of Alabama at Birmingham
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
1
2
3+
0

What questions have other patients asked about this trial?

Is there a stipend? Is there any compensation? How long will the study last?
PatientReceived 2+ prior treatments
Does this study involves taking injections or oral medication?
PatientReceived no prior treatments

Why did patients apply to this trial?

I suffer with obesity. I found it interesting. please text 256-861-6838. Unable to get.motivated to lose weight.
PatientReceived 2+ prior treatments
Hoping this trial will help my diabetes get on track.
PatientReceived no prior treatments

How responsive is this trial?

Average response time
  • < 2 Days
Typically responds via
Phone Call
Email
Most responsive sites:
  1. University of Alabama at Birmingham: < 24 hours
Recent research and studies
~100 spots leftby Apr 2026